151.43
Precedente Chiudi:
$155.86
Aprire:
$156.73
Volume 24 ore:
575.19K
Relative Volume:
1.36
Capitalizzazione di mercato:
$9.10B
Reddito:
$354.82M
Utile/perdita netta:
$-462.76M
Rapporto P/E:
-18.68
EPS:
-8.105
Flusso di cassa netto:
$-460.07M
1 W Prestazione:
-5.97%
1M Prestazione:
-3.29%
6M Prestazione:
+3.29%
1 anno Prestazione:
-0.36%
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Nome
Ascendis Pharma A S Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ASND con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ASND
Ascendis Pharma A S Adr
|
151.43 | 9.10B | 354.82M | -462.76M | -460.07M | -8.105 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-07 | Iniziato | UBS | Buy |
2024-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
2024-06-25 | Aggiornamento | TD Cowen | Hold → Buy |
2024-05-31 | Iniziato | Stifel | Buy |
2023-12-20 | Iniziato | Jefferies | Buy |
2023-06-14 | Ripresa | Credit Suisse | Neutral |
2023-04-05 | Downgrade | Oppenheimer | Outperform → Perform |
2023-04-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2023-04-03 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-10-20 | Iniziato | Goldman | Buy |
2022-08-30 | Ripresa | Berenberg | Buy |
2022-03-28 | Ripresa | Wedbush | Outperform |
2022-03-15 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-03-01 | Iniziato | Citigroup | Buy |
2022-02-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
2022-01-06 | Iniziato | Cowen | Market Perform |
2021-12-08 | Iniziato | Wells Fargo | Overweight |
2021-10-20 | Downgrade | BofA Securities | Buy → Neutral |
2021-03-30 | Downgrade | Oppenheimer | Outperform → Perform |
2021-03-11 | Ripresa | Stifel | Buy |
2020-12-17 | Iniziato | Berenberg | Buy |
2020-09-14 | Ripresa | JP Morgan | Overweight |
2020-03-20 | Iniziato | Oppenheimer | Outperform |
2019-10-11 | Iniziato | Morgan Stanley | Overweight |
2019-03-25 | Iniziato | Evercore ISI | Outperform |
2019-01-24 | Iniziato | Cantor Fitzgerald | Overweight |
2019-01-24 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
2018-06-26 | Iniziato | Stifel | Buy |
2018-04-02 | Reiterato | Leerink Partners | Mkt Perform |
2017-05-11 | Iniziato | JP Morgan | Overweight |
2017-03-09 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
2017-02-09 | Iniziato | Credit Suisse | Outperform |
2016-09-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Autohome ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Inkl
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl
Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com
ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com
Ascendis Pharma launches $25 million share buyback - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World
Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
Ascendis Pharma target raised to $194 on positive trial results - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com
Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News
Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex
The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com
Ascendis Pharma A S Adr Azioni (ASND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):